Penn-led trial shows AZEDRA can be effective, safe for treatment of rare neuroendocrine tumors

(University of Pennsylvania School of Medicine) A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news